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AbstrACt
Introduction Circulating prostaglandin E2 levels are 
elevated in acutely decompensated cirrhosis and have 
been shown to contribute to immune suppression. Albumin 
binds to and inactivates this immune-suppressive lipid 
mediator. Human albumin solution (HAS) could thus be 
repurposed as an immune-restorative drug in these 
patients. This is a phase III randomised controlled trial 
(RCT) to verify whether targeting a serum albumin level 
of ≥35 g/L in hospitalised patients with decompensated 
cirrhosis using repeated intravenous infusions of 20% HAS 
will reduce incidence of infection, renal dysfunction and 
mortality for the treatment period (maximum 14 days or 
discharge if <14 days) compared with standard medical 
care.
Methods and analysis Albumin To prevenT Infection 
in chronic liveR failurE stage 2 is a multicentre, open-
label, interventional RCT. Patients with decompensated 
cirrhosis admitted to the hospital with a serum albumin 
of <30 g/L are eligible, subject to exclusion criteria. 
Patients randomised to intravenous HAS will have this 
administered, according to serum albumin levels, for 
up to 14 days or discharge. The infusion protocol aims 
to increase serum albumin to near-normal levels. The 
composite primary endpoint is: new infection, renal 
dysfunction or mortality within the trial treatment period. 
Secondary endpoints include mortality at up to 6 months, 
incidence of other organ failures, cost-effectiveness and 
quality of life outcomes and time to liver transplant. The 
trial will recruit 866 patients at more than 30 sites across 
the UK.
Ethicsanddissemination Research ethics approval was 
given by the London-Brent research ethics committee (ref: 
15/LO/0104). The clinical trials authorisation was issued 
by the medicines and healthcare products regulatory 
agency (ref: 20363/0350/001–0001). The trial is registered 
with the European Medicines Agency (EudraCT 2014-
002300-24) and has been adopted by the National 
Institute for Health Research (ISRCTN 14174793). This 
manuscript refers to version 6.0 of the protocol. Results 
will be disseminated through peer-reviewed journals 
and international conferences. Recruitment of the first 
participant occurred on 25 January 2016.
IntroduCtIon 
Liver disease is an increasing cause of 
mortality currently in the UK and is the 
fifth most common cause of death.1 These 
deaths are predicted to double over the 
next 20 years2. Mortality is mainly seen in 
the middle-aged group. Liver disease has 
surpassed lung and breast cancers as the 
leading causes of years of working life lost, 
and are set to overtake ischaemic heart 
disease within 2–3 years3.
Patients with complications of liver failure 
secondary to liver cirrhosis are described as 
decompensated patients. They are highly 
prone to bacterial infection4 secondary 
to immune dysfunction,5 with nosoco-
mial (hospital-acquired) infection rates of 
35% compared with 5% in non-cirrhotic 
patients.6 7 Of those who develop infection 
with organ dysfunction, 60%–95% will die, 
often following prolonged intensive care unit 
strengths and limitations of this study
 ► This is the first prospective, interventional ran-
domised controlled trial with the primary aim of as-
sessing the effects of serum albumin targeted 20% 
human albumin solution (HAS) infusions on infec-
tion, organ failure and death in hospitalised patients 
with decompensation of liver cirrhosis.
 ► Study design was optimised by a prior 80-patient 
feasibility study.
 ► Cost-effectiveness and quality of life assessment 
will review whether any outcomes are sustainable 
and feasible in a national health service setting.
 ► The study is unblinded to site investigators due to 
lack of agreement regarding the control infusion flu-
id and high cost required.
 ► Patients in the control arm may receive 20% HAS as 
part of current international guidance as it would be 
unethical to withhold this in certain situations.
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(ICU) admission.8 There is, however, no medical strategy 
to restore immune competence.
It has been demonstrated that elevated circulating pros-
taglandin E2 (PGE2) levels contribute to immune suppres-
sion in acutely decompensated patients.9 The plasma 
protein albumin binds and catalyses the inactivation of 
PGE2.
10 The binding capacity of endogenous albumin 
is known to be defective in cirrhosis11 12 and improves 
following albumin infusions.13 Albumin is synthesised in 
the liver and levels fall as the synthetic function of the liver 
declines in advanced cirrhosis. Therefore, low albumin 
levels, with defective binding function, make PGE2 more 
bioavailable. We found a serum albumin of <30 g/L 
predicted plasma-induced macrophage dysfunction in a 
small cohort of decompensated cirrhosis patients9 and 
this was reversed when albumin levels were increased 
to ≥30 g/L. This finding has recently been validated in 
a multicentre clinical trial13; however, it is not known if 
these ex vivo observations translate into an improvement 
in clinical outcomes.
We propose a novel strategy to repurpose 20% human 
albumin solution (HAS) as an immune-restorative drug 
in patients with decompensated liver cirrhosis with the 
aim of maintaining serum albumin at near-normal levels.
The Albumin To prevenT Infection in chronic liveR 
failurE (ATTIRE) phase II single-arm, multicentre feasi-
bility trial14 (n=80) verified that daily intravenous human 
albumin infusions restored serum albumin levels to near 
normal in hospitalised patients with decompensated 
cirrhosis, that it was safe and that there was physician 
equipoise prior to proceeding to a large randomised 
controlled trial (RCT).15 It has also allowed refinement of 
our definitions of RCT outcomes.
This phase III RCT (n=866) will assess the impact of 
20% HAS treatment on the incidence of nosocomial 
infections, organ dysfunction and mortality in patients 
admitted to hospital with decompensation of liver 
cirrhosis.
MEthods And AnAlysIs
Primary objective
To verify whether raising and maintaining serum 
albumin levels ≥30 g/L in patients admitted with decom-
pensated cirrhosis using repeated 20% HAS infusions 
will reduce incidence of infection, renal dysfunction and 
mortality for the treatment period (maximum 14 days or 
discharge if <14 days) compared with standard medical 
care (figure 1). To raise and maintain serum albumin 
levels above 30 g/L, 20% HAS will be prescribed and 
administered in the intervention arm if levels are below 
35 g/L.
Secondary objectives are to assess the impact of the 
intervention on development of other organ dysfunction 
(cardiac, respiratory, brain and liver), cost-effectiveness, 
quality of life (QOL) and sustainability of any outcomes 
over a 6-month follow-up period.
trial design
This is a multicentre, open-label, RCT in which patients 
will either be treated with 20% HAS to raise and maintain 
serum albumin above 30 g/L or continue to receive their 
usual standard of care treatment. Eight hundred sixty-six 
sequential patients admitted to 30 UK participating hospi-
tals with a clinical diagnosis of cirrhosis and decompensa-
tion will be screened using the inclusion and exclusion 
criteria (table 1). Decompensation includes: jaundice, 
ascites, hepatic encephalopathy, variceal bleeding, coag-
ulopathy and hepatorenal syndrome (HRS).
As advanced liver disease requires frequent hospital 
readmissions, patients may be enrolled in the RCT more 
than once, with a 30-day ‘washout period’ following 
discharge after the first enrolment, during which time 
they cannot be enrolled for a second time. This is to 
account for albumin’s half-life of 18–21 days16. Patients 
re-entering the trial in this way will be rerandomised, so 
that each enrolment will be considered as an indepen-
dent patient ‘presentation’.17
To ensure homogeneity in the approach to patient 
recruitment, intervention and data collection, all sites 
received introduction training and regular follow-up 
re-training plus monitoring and support visits from the 
sponsor.
Clinical trial endpoints
Primary endpoint
A composite endpoint comprising incidence of infection, 
renal dysfunction and mortality within the treatment 
period (for a maximum of 14 days OR when the patient is 
considered fit for discharge if <14 days).
The three components of the composite endpoint are:
1. New infection: indicated by clinician diagnosis and 
clinical evidence provided on completed infection 
case report form (CRF). Blinded data from a clinically 
representative sample of patients will be scrutinised for 
the presence of infection by a clinical trial endpoint 
review committee. The committee will contain micro-
biologists who will validate the presence of infection 
according to peer reviewed criteria18 (see online sup-
plementary appendix 1).
2. Renal dysfunction: a serum creatinine increase of 
≥50% as compared with serum creatinine at randomis-
ation OR the patient is initiated on renal replacement 
support (either haemodialysis or haemofiltration) 
OR a rise in serum creatinine of ≥26.5 μmol/L within 
48 hours.
3. Mortality
Primary endpoint data will be recorded throughout 
the treatment period; however, only contributing events 
captured on the treatment day 3 CRF through to the 
day 15 CRF (the end of treatment examination day) 
will contribute to the primary outcome. This allows the 
biological effect of albumin to be established at least 
24 hours following initiation of treatment.
If the participant is discharged or deemed medically fit 
for discharge prior to day 15, no further primary outcome 
 o
n
 23 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023754 on 21 October 2018. Downloaded from 
3China L, et al. BMJ Open 2018;8:e023754. doi:10.1136/bmjopen-2018-023754
Open access
data will be measured after this date, as this will signal the 
end of the participant’s treatment period.
Secondary endpoints
1. Mortality at 28 days postrandomisation and at 3 and 
6 months postdischarge
2. Time to outcome (first event of infection/renal 
dysfunction/death)
3. Incidence of respiratory, circulatory and cerebral 
dysfunction during the treatment period (based 
on modified components of the Chronic liver 
failure-sequential organ failure assessment (CLIF-
SOFA)19 score).
4. Incidence of liver transplant within 6 months of 
treatment
5. Total amount of HAS administered during the treat-
ment period
6. Duration of hospital stay
7. Change in prognostic score (assessed by Model for 
End Stage Liver Disease (MELD)) between randomi-
sation and end of treatment period.
8. Days in ICU during treatment period
Figure 1 Overview of Albumin To prevenT Infection in chronic liveR failurE (ATTIRE) randomised controlled trial (RCT) study 
protocol. HAS, human albumin solution; HRS, hepatorenal syndrome; LVP, large volume paracentesis; QOL, quality of life; SBP, 
spontaneous bacterial peritonitis. 
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9. Incremental cost and cost-effectiveness up to 
6 months postdischarge
10. Impact on QOL up to 6 months postdischarge
11. Safety and tolerability of HAS as indicated by serious 
adverse events
12. Use of terlipressin for (1) renal dysfunction, (2) hy-
potension and (3) variceal bleeding.
Patients in the RCT will be followed up 3 and 6 months 
(+/−1 month) following discharge from hospital. Explor-
atory objectives are listed in online supplementary 
appendix 2.
Patient population
This will include all patients admitted to hospital with 
complications of decompensated liver cirrhosis and 
serum albumin <30 g/L, aged over 18 years with antici-
pated hospital length of stay of 5 or more days at trial 
enrolment, which should be no later than 72 hours from 
admission. This is subject to exclusion criteria as detailed 
in table 1. The diagnosis of cirrhosis will be made by 
the clinical team as per standard UK practice and does 
not require liver biopsy or imaging. Acute decompen-
sation of liver cirrhosis associated with organ failures is 
termed ACLF (acute on chronic liver failure). ACLF has a 
number of definitions20 21 based on the SOFA score, all are 
associated with a poor prognosis. This study will include 
patients with decompensated cirrhosis with and without 
ACLF; it will also record the development of ACLF during 
the study treatment period.
Consent
Patient information sheets (see online supplementary 
appendix 3) will be given to and discussed with poten-
tial patients before consent is sought. Informed consent 
will be obtained from each participant or his or her legal 
representative. Patients who lack mental capacity, for any 
reason, are not excluded from the trial. An important 
subgroup of patients will have hepatic encephalopathy 
and these patients may lack capacity to consent; however, 
these patients may be among those that receive maximum 
benefit from the intervention.21–23 In this case, consent 
will be sought from an appropriate legal representative 
independent of the research team as per current UK clin-
ical trials regulations.24
Intervention
After randomisation (when serum albumin is <30 g/L) 
patients will receive either daily dose of 20% HAS intrave-
nously if their serum albumin level is less than 35 g/L (at 
approximately 100 mL/hour) or standard medical care 
(which may include 20% HAS infusions for indications listed 
in established guidelines only; see below) for a maximum of 
14 days or discharge (if <14 days). The volume of HAS each 
day will be determined by the patient’s serum albumin level 
on that day (or the closest previous measurement if there 
are no results from that day available).
Table 2 shows the suggested dosing protocol for albumin 
administration in the treatment arm group. This is a 
suggested regimen and responsible clinicians are given flex-
ibility to alter this depending on the clinical situation. The 
effectiveness of this protocol, and approach, was verified 
in the ATTIRE feasibility study.15 Differing regimens may 
be used to cover large volume paracentesis (LVP) (8 g of 
albumin per litre of ascites drained) or treat HRS (1 g of 
albumin per kilogram of body weight) as per international 
guidelines25 26 but HAS must be prescribed and given if 
serum albumin <35 g/L unless there are any safety concerns. 
All variations will be recorded in the patient’s daily CRF.
Twenty per cent HAS will only be given in the standard of 
care arm if the patient requires large volume paracentesis 
Table 1 Patient selection criteria
Patient inclusion criteria Patient exclusion criteria
All patients admitted to 
hospital with acute onset or 
worsening of complications of 
cirrhosis
Advanced hepatocellular 
carcinoma with life 
expectancy of less than 
8 weeks
Over 18 years of age Patients who will receive 
palliative treatment only 
during their hospital 
admission
Predicted hospital admission 
≥5 days at trial enrolment, 
which must be within 72 hours 
of admission
Patients who are pregnant
Serum albumin <30 g/L at 
screening
Known or suspected severe 
cardiac dysfunction
Documented informed 
consent to participate (or 
consent given by a legal 
representative)
Any clinical condition which 
the investigator considers 
would make the patient 
unsuitable for the trial
The patient has been 
involved in a clinical trial of 
investigational medicinal 
products (IMPs) within the 
previous 30 days that would 
impact on their participation 
in this study
Trial investigators unable to 
identify the patient (by NHS 
number)
NHS, National Health Service. 
Table 2 Treatment arm dosing protocol for 20% human 
albumin solution (HAS) administration (amounts per day) as 
advised by measured serum albumin level on that day
Patient’s serum albumin 
level
Amount of 20% HAS to be 
administered
≥35 g/L none
30–34 g/L 100 mL
26–29 g/L 200 mL
20–25 g/L 300 mL
<20 g/L 400 mL
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or has spontaneous bacterial peritonitis (SBP) or HRS (as 
per established guidelines26–28). This needs to be clearly 
recorded in the patient’s CRF, and if HAS is given for any 
other indication in the Standard of Care arm, this will be 
considered a protocol deviation. The administration of 
HAS in the Standard of Care arm will be closely moni-
tored by the Independent Data Monitoring Committee 
(IDMC).
Randomisation will use a minimisation algorithm incor-
porating a random element, stratifying by centre, MELD 
score, and number of organ dysfunctions, serum albumin 
level and if antibiotics are currently being prescribed. To 
ensure maximum balance is achieved across the stratifi-
cation factors, minimisation will be carried out on these 
factors separately.
Evaluations during and after treatment
Clinical, biochemical, microbiological, health economic 
and QOL data will be collected during the trial treatment 
period (see online supplementary appendix 4) using 
information from hospital notes that is recorded as stan-
dard of care. There is follow-up at 3 and 6 months. The 
blood, urine and stool samples collected for immune 
function tests will be analysed in a blinded fashion at a 
central site.
Patient and public involvement
Patients who have had a previous diagnosis of liver 
cirrhosis were involved in the development of the 
research question and outcome measures. Patient feed-
back led to the addition of QOL evaluation. The study 
protocol and patient information leaflets were reviewed 
by our patient representatives with positive feedback. In 
addition, an independent patient representative sat on 
the ethics approval panel. Results will be disseminated to 
patients via open access publication and our local trials 
teams.
statistical considerations
Sample size
A 30% incidence of nosocomial infection in acute decom-
pensated cirrhosis patients is well documented with up to 
30% of these patients developing organ dysfunction21 29 
and an overall mortality of 38% at 1 month.18 21 29 These 
figures are supportive of 30% as a conservative estimate 
for the composite primary endpoint of incidence of new 
infection, renal dysfunction or mortality up to 14 days 
from randomisation.
We have assumed that the ‘immune-restorative’ albumin 
treatment would reduce this rate by 30% to a rate of 21%, 
which would be considered clinically relevant. Three 
hundred eighty-nine patients per arm would be sufficient 
to detect such a difference with 80% power at a significance 
level of 0.05. Allowing for loss to follow-up/withdrawal of 
10% from the trial, we will aim to recruit 433 to each arm 
(866 in total).
statistical evaluation
A detailed statistical analysis plan will be written and 
approved by the Trial Steering Committee (TSC) before 
the substantive analysis of unblinded trial data.
Baseline characteristics will be summarised by treat-
ment using appropriate descriptive statistics, means and 
SD for approximately normally distributed variables, 
medians and IQRs for non-normally distributed variables 
and counts (percentages) for categorical variables.
Primary outcome
The primary outcome is the difference in event rates, 
according to treatment, of the composite endpoint of 
infection, renal dysfunction and mortality within the 
intervention period (from ≥24 hours from the start of 
treatment/randomisation up to a maximum of 14 days or 
up to discharge if this is prior to 14 days).
Since the primary outcome has a binary classification, 
logistic regression will be used to determine whether there 
is any difference in rates due to treatment, by inclusion of 
a binary covariate indicating treatment. The results will 
be adjusted for predetermined prognostic factors used 
as stratifying variables in the randomisation, which shall 
be included as additional covariates in the model. The 
model coefficient due to treatment will give an estimate 
of the difference in log odds, or equivalently (exponenti-
ated to give) an estimate of the odds multiplier, that is, the 
change in odds of a negative outcome on the composite 
endpoint due to treatment with albumin. It is expected 
that this effect will be negative, so that treatment with 
albumin is seen to reduce the odds of a negative outcome. 
A reduction from 30% to 21% would be associated with a 
reduction in odds of around 38%. Predicted probabilities 
will be presented for the composite outcome for each of 
the treatment arms, adjusted for the model covariates.
The effect of treatment on the individual components, 
infection, renal dysfunction and mortality will be reported 
separately.
Secondary and exploratory outcomes
Secondary and exploratory outcomes will be handled 
similarly. Continuous secondary outcome measures will 
be analysed using a linear regression model, and time-
to-event outcomes using Kaplan-Meier plots and Cox’s 
proportional hazards models where covariate adjustment 
is necessary.
All statistical tests will use a two-sided p value of 0.05, 
unless otherwise specified, and all CIs presented will 
be 95% and two-sided. All statistical analyses will be 
performed using Stata (StataCorp, College Station, Texas, 
USA).
Economic evaluation
The economic evaluation will consist of two parts. 
The primary analysis will be a decision analytic model 
comparing the expected lifetime costs and benefits of 
treatment reported in terms of the cost per incremental 
quality-adjusted life-years (QALYs) gained. QALYs will 
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be calculated based on the health-related QOL (HRQL) 
and mortality data collected during the trial. HRQL will 
be measured according to the 5 level EQ-5D (EQ-5D-5L) 
(www. euroqol. org), which we will collect at baseline, 
discharge, 3 months and 6 months (+/–1 month) for each 
individual patient. If patients are rerandomised, they will 
have separate follow-up events for each episode of reran-
domisation, unless the patient is rerandomised within 
the follow-up phase of the study. Utility scores will be 
calculated using UK-specific tariffs and adjusting for base-
line differences in patients in the trial arms if necessary. 
These will be extrapolated over the expected lifetime of 
the patient and where necessary will draw on the existing 
literature. The final form of the decision analytic model 
will be determined during the trial period. Appropriate 
methods for estimating changes in health over time, such 
as state-transition models, will be given consideration.
The secondary economic analysis will be a ‘within-trial’ 
analysis, reporting on the incremental cost and benefits 
observed during the trial period and follow-up periods. 
The cost-effectiveness measures in the within-trial anal-
ysis will be the incremental cost per infection avoided 
and the incremental cost per QALY gained. Costs will be 
measured as described below. Infections avoided will be 
derived from the primary outcome in the trial.
Patient resource use will be assessed using hospital 
patient records and a self-complete resource use form, 
the client services receipt inventory (CSRI). The volume 
of resource use for each cost component will be measured 
directly in the trial from patient records and using the 
CSRI. A detailed economic evaluation analysis plan will 
be developed for approval by the TSC.
dIsCussIon
ATTIRE is a UK multicentre trial that aims to evaluate the 
repurposing of HAS as an immune-restorative drug. This 
protocol describes the RCT which will determine if admin-
istering daily 20% HAS infusions in order to increase 
serum albumin to near-normal levels after admission to 
hospital will reduce rates of infection, renal failure and 
death in patients with decompensation of liver cirrhosis.
In liver cirrhosis, current evidence-based guidance26–28 
advocates the use of HAS in large-volume paracentesis,30 
HRS31 and SBP.32 33 The mechanism behind current usage 
of albumin is that of volume expansion. However, many 
hepatologists believe albumin has other medicinal prop-
erties; however, a large-scale interventional clinical trial 
is yet to support this hypothesis. Ex vivo analysis from the 
ATTIRE feasibility study supported an immune-restor-
ative role for albumin13; however, it is unknown whether 
this correlates with clinical outcome. Our inclusion 
criteria are broad and designed to represent the decom-
pensated cirrhotic population admitted to UK hospitals 
in order to make trial outcomes highly relevant in an 
era of soaring liver disease with few available treatment 
options. Preventing a liver cirrhosis-related infection 
could potentially provide a bridge to liver transplanta-
tion, which represents the only curative option for these 
patients.
The design of this RCT has been refined based on 
the outcomes of an 80-patient interventional feasibility 
study.15 Our targeted infusion protocol (table 2) was effec-
tive at increasing serum albumin, even in patients with a 
very low starting serum albumin. Many hepatology trials 
focus solely on 28-day survival; however, mortality requires 
large sample size and may be caused by other factors 
unrelated to infection. We considered that endpoints for 
interventions to prevent infection should be assessed at 
an earlier stage during the patient admission using ward-
based clinical measures and laboratory data. Multiple 
components of a primary composite endpoint were tested 
in our feasibility study.15 Defining infection according to 
clinician diagnosis, triggering completion of an infection 
CRF, with a substantial proportion blindly scrutinised by 
a microbiology panel worked well in our feasibility study. 
Patients that developed renal dysfunction as assessed by 
an increase in serum creatinine had a poor prognosis, as 
expected. However, only one patient developed cerebral 
dysfunction reflecting severe hepatic encephalopathy 
(>grade 3) suggesting under-reporting and the majority 
of patients that solely triggered respiratory and cardio-
vascular endpoints had a good outcome. This is coun-
terintuitive as organ dysfunction is a key predictor of 
poor prognosis and we consider our data cast significant 
doubt over whether these dysfunctions can be recorded 
accurately in largely ward-based patients across multiple 
sites. This precludes their use as part of our RCT primary 
composite endpoint; although these will be reported.
Studies evaluating the safety of HAS infusions have 
generally shown it to be a safe treatment.30 34–36 The 
main concerns in the cirrhotic population are related 
to volume overload leading to pulmonary oedema and 
increase in portal pressure leading to variceal bleeding. 
A recent interventional trial in septic decompensated 
patients reported an 8.3% rate of pulmonary oedema 
in the albumin treatment group.37 However, the weight-
based albumin dosing regimen on days 1 and 3 in this 
study led to much larger volumes of albumin prescribed 
than suggested in our protocol for these days. This and 
other studies in cirrhosis have not reported an increased 
incidence in variceal bleeding.30 33 38
A challenge this study faces is the lack of a comparator 
infusion fluid in the control arm and hence the impos-
sibility of site investigator and patient blinding. We had 
therefore considered comparison with another fluid such 
as 0.9% sodium chloride; however, this posed a number 
of problems. Physician preference for resuscitation 
fluid varies substantially and, in preliminary discussions, 
many objected to the additional salt load associated with 
0.9% sodium chloride, in the non-albumin arm, if the 
patient did not require fluid resuscitation. Administra-
tion of 20% HAS for SBP, LVP and HRS is standard of 
care, and therefore, if patients in either arm developed 
these complications during their admission, they would 
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have to be unblinded to see if they were already receiving 
20% HAS as part of the trial. As a significant number of 
patients do develop these complications, the consequent 
number of unblinded patients could have rendered the 
process invalid. Therefore, the RCT had to be an open-
label study. This risks biasing adverse event reporting in 
the treatment arm, making albumin appear unsafe. We 
therefore felt that an open-label trial design versus a 
comparator arm of current standard of care was the only 
pragmatic solution. It could be argued that any improved 
outcome in the albumin treatment arm may simply be 
due to additional fluid resuscitation. The mean volume 
of 20% HAS infused over the treatment period (14 days) 
was 1 L in our feasibility study.
The regulation of HAS administration in the standard 
of care (control) arm poses a challenge as HAS is routinely 
used in clinical practice based on evidence-based guide-
lines.26–28 The protocol allows use for these indications. 
If HAS is administered to control arm patients outside 
of current evidence-based guidance, this will be defined 
as a protocol deviation and the IDMC will be monitoring 
these events closely.
The ATTIRE RCT (n=866, up to 40 centres) began 
recruitment in April 2016 and aims to complete in 
December 2019. The medicinal properties of albumin 
in the hepatological community have long been ques-
tioned. The outcomes of this large, multicentre, RCT will 
be highly relevant to improving the care of hospitalised 
patients with decompensation of chronic liver disease.
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